{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:51:41Z","timestamp":1786114301831,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,17]],"date-time":"2027-07-17T00:00:00Z","timestamp":1815782400000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CGCATF-2021\/100003"],"award-info":[{"award-number":["CGCATF-2021\/100003"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA278700-01"],"award-info":[{"award-number":["CA278700-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcyt.2026.102914","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:41:12Z","timestamp":1779464472000},"page":"102914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A 38-color spectral panel for cost efficient characterization of T cell therapy products"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7178-5658","authenticated-orcid":false,"given":"Gage D.","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imani A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-9090","authenticated-orcid":false,"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8917-7280","authenticated-orcid":false,"given":"Christopher A.","family":"Lazarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102914_bib0001","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2022.02.002","article-title":"The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease","volume":"30","author":"Hont","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102914_bib0002","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.19.00177","article-title":"Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic t lymphocytes: a phase I study","volume":"37","author":"Hont","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.jcyt.2026.102914_bib0003","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/bloodadvances.2021006831","article-title":"Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT","volume":"6","author":"Kinoshita","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102914_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/bloodadvances.2021005343","article-title":"Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed\/refractory Hodgkin lymphoma","volume":"6","author":"Dave","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102914_bib0005","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","article-title":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102914_bib0006","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.bbmt.2018.04.030","article-title":"Antiviral T cells for adenovirus in the pretransplant period: a bridge therapy for severe combined immunodeficiency","volume":"24","author":"Miller","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102914_bib0007","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41467-024-49595-1","article-title":"Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment","volume":"15","author":"Levine","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102914_bib0008","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1182\/bloodadvances.2022009468","article-title":"Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia","volume":"7","author":"Shahid","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102914_bib0009","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1172\/JCI137181","article-title":"Immune profiling of pediatric solid tumors","volume":"130","author":"Terry","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jcyt.2026.102914_bib0010","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","article-title":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102914_bib0011","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/bioinformatics\/bts082","article-title":"Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays","volume":"28","author":"Aghaeepour","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcyt.2026.102914_bib0012","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1479-5876-9-138","article-title":"Biomarkers in T cell therapy clinical trials","volume":"9","author":"Kalos","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2026.102914_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00107","article-title":"Immune responses to cancer: are they potential biomarkers of prognosis?","volume":"3","author":"Whiteside","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102914_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830773","article-title":"Monitoring of circulating CAR T cells: validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel","volume":"13","author":"Peinelt","year":"2022","journal-title":"Front. Immunol"},{"key":"10.1016\/j.jcyt.2026.102914_bib0015","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.19.00177","article-title":"Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study","volume":"37","author":"Hont","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.jcyt.2026.102914_bib0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN\u03b3 in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jcyt.2026.102914_bib0017","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102914_bib0018","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1074-7613(00)80197-1","article-title":"Antigen-Specific regulation of T cell\u2013mediated cytokine production","volume":"12","author":"Slifka","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2026.102914_bib0019","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/cancers13030564","article-title":"Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy","volume":"13","author":"Mercogliano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2026.102914_bib0020","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2026.102914_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102914_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060031","article-title":"Co-Stimulation through 4-1BB\/CD137 improves the expansion and function of CD8+ melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy","volume":"8","author":"Chacon","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcyt.2026.102914_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.16","article-title":"OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer","volume":"5","author":"Montler","year":"2016","journal-title":"Clin & Trans Imm"},{"key":"10.1016\/j.jcyt.2026.102914_bib0024","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/hep.24149","article-title":"Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma","volume":"53","author":"Mizukoshi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jcyt.2026.102914_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/cpim.26","article-title":"Basic multicolor flow cytometry","volume":"117","author":"Maciorowski","year":"2017","journal-title":"CP in Immunol"},{"key":"10.1016\/j.jcyt.2026.102914_bib0026","article-title":"Flow cytometry: an overview","volume":"120","author":"McKinnon","year":"2018","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.jcyt.2026.102914_bib0027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcyt.2023.10.005","article-title":"Review of flow cytometry as a tool for cell and gene therapy","volume":"26","author":"Lazarski","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102914_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.815828","article-title":"CyTOF\u00ae for the Masses","volume":"13","author":"Iyer","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102914_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/0471142956.cy0127s63","article-title":"Spectral flow cytometry","volume":"63","author":"Nolan","year":"2013","journal-title":"CP Cytometry"},{"key":"10.1016\/j.jcyt.2026.102914_bib0030","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cyto.a.24566","article-title":"The evolution of spectral flow cytometry","volume":"101","author":"Nolan","year":"2022","journal-title":"Cytometry Pt A"},{"key":"10.1016\/j.jcyt.2026.102914_bib0031","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcyt.2020.03.110","article-title":"Dissecting adipose tissue derived mesenchymal stromal cell heterogeneity using single cell rna sequencing and multiparameter spectral flow cytometry","volume":"22","author":"Brooks","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102914_bib0032","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/j.jcyt.2025.03.330","article-title":"Multi-donor characterization of degradable microscaffolds for therapeutic T cell manufacturing","volume":"27","author":"Ochoa","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102914_bib0033","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcyt.2023.10.005","article-title":"Review of flow cytometry as a tool for cell and gene therapy","volume":"26","author":"Lazarski","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102914_bib0034","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41592-023-02042-3","article-title":"A practitioner\u2019s view of spectral flow cytometry","volume":"21","author":"Sharma","year":"2024","journal-title":"Nat Methods"},{"key":"10.1016\/j.jcyt.2026.102914_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/cpcy.70","article-title":"Panel design and optimization for high-dimensional immunophenotyping assays using spectral flow cytometry","volume":"92","author":"Ferrer-Font","year":"2020","journal-title":"CP Cytometry"},{"key":"10.1016\/j.jcyt.2026.102914_bib0036","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/ijlh.14098","article-title":"Full spectrum flow cytometry in the clinical laboratory","volume":"45","author":"Brestoff","year":"2023","journal-title":"Int J Lab Hematology"},{"key":"10.1016\/j.jcyt.2026.102914_bib0037","article-title":"Immune cell profiling of peripheral blood as signature for response during checkpoint inhibition across cancer types","volume":"11","author":"Araujo","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jcyt.2026.102914_bib0038","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1038\/s41467-019-13055-y","article-title":"Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets","volume":"10","author":"Belkina","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102914_bib0039","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry Pt A"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:42:24Z","timestamp":1785962544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1465324926008753"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102914","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 38-color spectral panel for cost efficient characterization of T cell therapy products","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102914"}}